DPP4 and plasma cell myeloma: In summary, to overcome both innate and acquired refractoriness of myeloma cells with CD26 antigen loss to CD26mAb, the concurrent use of HDACi confers therapeutic benefit by the induction of CD26 expression in myeloma cells.